Literature DB >> 18419442

A nationally coordinated laboratory system for human avian influenza A (H5N1) in Thailand: program design, analysis, and evaluation.

Rungrueng Kitphati1, Anucha Apisarnthanarak, Malinee Chittaganpitch, Pranee Tawatsupha, Wattana Auwanit, Pilaipan Puthavathana, Prasert Auewarakul, Mongkol Uiprasertkul, Linda M Mundy, Pathom Sawanpanyalert.   

Abstract

BACKGROUND: The first phase of national surveillance for avian influenza (H5N1) human disease in Thailand occurred over a 4-month period that began on 1 December 2003. Subsequently, a nationally coordinated laboratory system (NCLS) for avian influenza (H5N1) was created to assess population-based surveillance, specimen procurement, case detection, and reporting at the national level.
METHODS: We conducted a pre- and postintervention study to evaluate the NCLS designed during the 6-week interval from 1 April through 15 May 2004. During the pre-NCLS period (1 December 2003 through 31 March 2004), 12 cases of human avian influenza (H5N1) were confirmed. During the post-NCLS period (16 May 2004 through 31 December 2006), interventions were implemented for human avian influenza (H5N1) surveillance, case detection, and expedited, computer-based reporting.
RESULTS: During the pre- and post-NCLS periods, 777 (85%) of 915 and 10,434 (95%) of 11,042 clinical respiratory specimens, respectively, were adequate for confirmatory testing (P<.001), the median time from procurement to results decreased from 17 days (range, 14-24 days) to 1.8 days (range, 0.25-4 days; P<.001), and the duration of specimen shipment decreased from 46.5 h to 21.1 h (P<.001). Thirteen cases of avian influenza (H5N1) were detected during the 31-month postintervention period. H5N1 reverse-transcriptase polymerase chain reaction and real-time reverse-transcriptase polymerase chain reaction sensitivity was 100% and specificity was 99.8%.
CONCLUSIONS: The NCLS exemplifies a systematic approach to national surveillance for avian influenza A (H5N1). This NCLS program in Thailand serves as a model for human avian influenza (H5N1) preparedness that can be adopted or modified for use in other countries.

Entities:  

Mesh:

Year:  2008        PMID: 18419442     DOI: 10.1086/586752

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  4 in total

1.  A comparison of clinical and epidemiological characteristics of fatal human infections with H5N1 and human influenza viruses in Thailand, 2004-2006.

Authors:  Vivek Shinde; Wanna Hanshaoworakul; James M Simmerman; Ubolrat Narueponjirakul; Wiwan Sanasuttipun; Suchada Kaewchana; Darin Areechokechai; Kumnuan Ungchusak; Alicia M Fry
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

2.  An early report from newly established laboratory-based influenza surveillance in Lao PDR.

Authors:  Phengta Vongphrachanh; James M Simmerman; Darouny Phonekeo; Vimatha Pansayavong; Thongchanh Sisouk; Somvay Ongkhamme; Gary T Bryce; Andrew Corwin; Juliet E Bryant
Journal:  Influenza Other Respir Viruses       Date:  2010-03       Impact factor: 4.380

3.  Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome.

Authors:  Wanna Hanshaoworakul; James Mark Simmerman; Ubolrat Narueponjirakul; Wiwan Sanasuttipun; Vivek Shinde; Suchada Kaewchana; Darin Areechokechai; Jens Levy; Kumnuan Ungchusak
Journal:  PLoS One       Date:  2009-06-25       Impact factor: 3.240

4.  What is the optimal therapy for patients with H5N1 influenza?

Authors:  Nicholas J White; Robert G Webster; Elena A Govorkova; Timothy M Uyeki
Journal:  PLoS Med       Date:  2009-06-23       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.